CHEK2 and breast cancer: Because the BARD1 contribution to BC risk has been determined by us to be at the borderline of low and moderate levels, it may suggest that BARD1 mutations contribute to a polygenic model [92,93], like for mutations of lower penetrance in other genes, including CHEK2 or ATM.